Press Releases
- New data to be presented at the 2013 ASCO Annual Meeting show Active Biotech's commitment to oncology research May 16, 2013 08:30 (CEST)
- Active Biotech AB Interim Report January - March 2013 April 25, 2013 08:30 (CEST)
- Active Biotech and Ipsen update the analysis plan for the 10TASQ10 trial evaluating tasquinimod in the treatment of prostate cancer April 25, 2013 07:00 (CEST)
- Annual Report 2012 Active Biotech AB (publ) April 15, 2013 10:00 (CEST)
- Active Biotech - Notice of Annual General Meeting of Shareholders April 11, 2013 08:30 (CEST)
- Number of shares and votes in Active Biotech March 28, 2013 08:30 (CET)
- EARLY VERSUS DELAYED TREATMENT WITH LAQUINIMOD DEMONSTRATED SIGNIFICANT REDUCTION IN RISK OF DISABILITY PROGRESSION - RESULTS OF THREE-YEAR ALLEGRO STUDY IN RELAPSING-REMITTING MULTIPLE SCLEROSIS March 21, 2013 13:00 (CET)
- FIRST PATIENT ENROLLED IN THIRD PHASE III STUDY OF ORAL LAQUINIMOD FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS March 6, 2013 14:00 (CET)
- Active Biotech raises SEK 270 million through a directed new issue to Investor March 6, 2013 08:30 (CET)
- Active Biotech AB Year-end report January - December 2012 February 14, 2013 08:30 (CET)